The results of several hypertension studies published in 2011 have contributed to our knowledge on the risks of and treatment for this condition, including the effects of slow-wave sleep, nocturnal dosing of medication, variability in post-stroke blood-pressure reduction, and the impacts of a low-sodium diet.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Qian Yang Yu Yin Granule-containing serum inhibits angiotensin II-induced proliferation, reactive oxygen species production, and inflammation in human mesangial cells via an NADPH oxidase 4-dependent pathway
BMC Complementary and Alternative Medicine Open Access 25 March 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hermida, R. C., Ayala, D. E., Mojon, A. & Fernandez, J. R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J. Am. Soc. Nephrol. 10.1681/ASN.2011040361.
Minutolo, R. et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am. J. Kidney Dis. 50, 908–917 (2007).
Rahman, M. & Appel, L. J. Should reducing nocturnal blood pressure be a therapeutic target in CKD? The time is ripe for a clinical outcomes trial. Am. J. Kidney Dis. 50, 901–903 (2007).
Black, H. R. et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289, 2073–2082 (2003).
Fung, M. M. et al. Decreased slow wave sleep increases risk of developing hypertension in elderly men. Hypertension 58, 596–603 (2011).
Sandset, E. C. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377, 741–750 (2011).
Aiyagari, V. & Gorelick, P. B. Management of blood pressure for acute and recurrent stroke. Stroke 40, 2251–2256 (2009).
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L. & Ebrahim, S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am. J. Hypertens. 24, 843–853 (2011).
Bibbins-Domingo, K. et al. Projected effect of dietary salt reductions on future cardiovascular disease. N. Engl. J. Med. 362, 590–599 (2010).
Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
G. L. Bakris has received grants/research support from Forest laboratories, Medtronic, Novartis, and Relypsa. He has acted as a consultant for Abbott, CVRx, Eli Lilly, FDA, Johnson & Johnson, Novartis, Servier, and Takeda.
Rights and permissions
About this article
Cite this article
Bakris, G. New insights—from risk factors to treatment implications. Nat Rev Cardiol 9, 75–77 (2012). https://doi.org/10.1038/nrcardio.2011.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.202
This article is cited by
-
Qian Yang Yu Yin Granule-containing serum inhibits angiotensin II-induced proliferation, reactive oxygen species production, and inflammation in human mesangial cells via an NADPH oxidase 4-dependent pathway
BMC Complementary and Alternative Medicine (2015)
-
Relationship between sleep quality and the level and pattern of BP
Nature Reviews Cardiology (2012)
-
Author's reply: Inadequate sleep equates to inadequate BP control
Nature Reviews Cardiology (2012)